Berberine-induced browning and energy metabolism: mechanisms and implications

pmc PeerJ PeerJ 2057 peerj PeerJ PeerJ 2167-8359 PeerJ, Inc PMC11809318 PMC11809318.1 11809318 11809318 39931072 10.7717/peerj.18924 18924 1 Food Science and Technology Drugs and Devices Nutrition Pharmacology Obesity Berberine-induced browning and energy metabolism: mechanisms and implications Alpaslan Ağaçdiken Aslıhan Göktaş Zeynep zeynep.goktas@hacettepe.edu.tr Department of Nutrition and Dietetics, Hacettepe University , Ankara , Turkey Antoun Jumana 7 2 2025 2025 13 478561 e18924 29 10 2024 13 1 2025 07 02 2025 10 02 2025 12 02 2025 © 2025 Alpaslan Ağaçdiken and Göktaş 2025 Alpaslan Ağaçdiken and Göktaş https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. Obesity has become a global pandemic. The approaches researched to prevent it include decreasing energy intake and/or enhancing energy expenditure. Therefore, research on brown adipose tissue is of great importance. Brown adipose tissue is characterized by its high mitochondrial content. Mitochondrial uncoupling protein 1 (UCP1) releases energy as heat instead of chemical energy. Thermogenesis increases energy expenditure. Berberine, a phytochemical widely used in Asian countries, has positive effects on body weight control. While the precise mechanisms behind this effect remain unclear, the adenosine monophosphate-activated protein kinase (AMPK) pathway is known to play a crucial role. Berberine activates AMPK through phosphorylation, significantly impacting brown adipose tissue by enhancing lipolytic activity and increasing the expression of UCP1, peroxisome proliferator-activated receptor γ-co-activator-1α (PGC1α), and PR domain containing 16 (PRDM16). While investigating the mechanism of action of berberine, both the AMPK pathway is being examined in more detail and alternative pathways are being explored. One such pathway is growth differentiation factor 15 (GDF15), known for its appetite-suppressing effect. Berberine’s low stability and bioavailability, which are the main obstacles to its clinical use, have been improved through the development of nanotechnological methods. This review examines the potential mechanisms of berberine on browning and summarizes the methods developed to enhance its effect. Adipose tissue Berberine Browning Obesity Thermogenesis The authors received no funding for this work. pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pmc-license-ref CC BY Introduction Obesity is a growing health concern worldwide, primarily driven by an imbalance between energy intake and expenditure ( Mayoral et al., 2020 ). This condition is associated with numerous metabolic disorders, including diabetes, cardiovascular diseases, and non-alcoholic fatty liver disease. Addressing obesity requires innovative approaches to increase energy expenditure while reducing energy storage. Brown adipose tissue (BAT) and the browning of white adipose tissue have emerged as promising therapeutic targets due to their roles in thermogenesis. This process converts stored energy into heat, thereby increasing total energy expenditure ( Marlatt & Ravussin, 2017 ). Berberine is a natural compound extensively utilized in traditional medicine across many Asian countries, especially China ( Wang et al., 2017 ). It is an isoquinoline alkaloid derived from several plants, such as Coptis chinensis , Berberis aquifolium , Berberis vulgaris , and Berberis aristate . Plants containing berberine have been used since ancient times. Coptis chinensis was used approximately 2,200 years ago for many health issues, particularly digestive system diseases ( Song, Hao & Fan, 2020 ). Approximately 1,500 years ago, Hongjing Tao mentioned the antidiabetic properties of berberine plants in the book “Note of Elite Physicians” ( Zhang et al., 2014a ). With technological advancements, the active component in these plants was identified as berberine, and consequently, the number of studies on berberine has recently increased. Berberine is believed to have numerous effects, including anti-obesity, hypoglycemic, hypolipidemic, hypotensive, and anti-inflammatory effects ( Hesari et al., 2018 ; Pirillo & Catapano, 2015 ; Yarla et al., 2016 ). Berberine is regarded as a potential anti-obesity agent because of its beneficial health effects. Berberine may increase thermogenesis, positively affect carbohydrate and lipid metabolism, suppress appetite, regulate intestinal permeability and hepatic gluconeogenesis, and modulate the microbiota ( Ilyas et al., 2020 ; Park, Jung & Shim, 2020 ; Rong et al., 2021 ; Wu et al., 2019 ; Zhang et al., 2020 , 2014c ). Taking 500 mg of berberine three times a day for 12 weeks may result in an average weight loss of approximately 2.3 kg (5 pounds) in individuals with obesity ( Hu et al., 2012 ). Berberine’s effect on thermogenesis is one of the most researched topics in this area. Although the exact mechanism is not yet fully understood, berberine induces adipose tissue browning and thermogenesis through various pathways ( Zhang et al., 2015 , 2008 ). This browning effect is considered a key mechanism contributing to berberine’s potential role in weight loss, as it promotes increased energy expenditure and thermogenesis, addressing the energy imbalance central to obesity. Beyond its metabolic effects, berberine is relatively safe. While berberine toxicity is rarely observed in animals, human studies have reported some mild side effects, such as gastrointestinal disturbances like diarrhea or constipation ( Imenshahidi & Hosseinzadeh, 2019 ; Zhang et al., 2010 ). Plants rich in berberine have been reported to be safe, showing no adverse effects on creatinine levels or liver function ( Linn et al., 2012 ). The side effects of berberine vary depending on the route of administration, dosage, and duration of use. This review aims to clarify the mechanisms of adipose tissue browning, which are essential for preventing obesity and its associated conditions, as well as to examine the effects of berberine on these mechanisms. There are different reviews in the literature examining the health effects of berberine. However, the number of articles presenting up-to-date data on the effects of berberine on adipose tissue browning and BAT activation is limited. Due to its low bioavailability, most studies on berberine are in vitro . Methods that could address this issue are provided in this review. Survey methodology In this review, articles containing the keywords “berberine” along with “brown adipose tissue,” “browning,” and “thermogenesis” in their titles or abstracts were searched in the PubMed, Science Direct, and Scopus databases. Since most of the relevant sources were recently published, no year restriction was applied. Only articles in English are considered. Research articles and reviews were included. A search using these criteria resulted in 278 research articles. After applying search filters, the titles of the resulting articles were reviewed first, followed by their abstracts. Articles with abstracts relevant to the research topic were then examined in detail. Studies that met the search criteria but were not relevant to the topic, did not provide sufficient data, or were inaccessible in full text were excluded. As a result, 10 studies relevant to the purpose of this review were included. Limiting the search to articles in English resulted in the exclusion of studies written in native languages from Asian countries, where the use of berberine is more prevalent. This can be considered a limitation of this study. The audience it is intended for This review may attract the attention of experts particularly interested in phytochemicals and adipose tissue, those investigating methods used to combat obesity, and those with an interest in nanotechnological approaches. With a better understanding of berberine’s effects on adipose tissue browning and the underlying mechanisms, it can be considered a potential drug for obesity prevention and/or treatment. Berberine and its pharmacokinetic properties Berberine (2,3-methylenedioxy-9,10-dimethoxyprotoberberine chloride) is yellow, odorless, and has a bitter taste ( Feng et al., 2019 ). It is more soluble in organic solvents and has low water solubility. Its molecular weight is 336.36 g/mol. It can be extracted from its source plants, or it can be synthesized ( Feng et al., 2019 ). Absorption and bioavailability While the health effects of berberine are intriguing, its low oral bioavailability (approximately 5%) is well-documented ( Habtemariam, 2020 ; Wang et al., 2017 ). One reason for its limited bioavailability is its high binding affinity for plasma proteins ( Mirhadi, Rezaee & Malaekeh-Nikouei, 2018 ). Therefore, research has focused on the metabolites of berberine and their health effects. Clinical evaluations have shown that intravenous administration of berberine increases its concentration in the blood ( Han et al., 2021 ). However, this increase can dangerously lower blood pressure, potentially leading to death. Therefore, oral intake is safer than intravenous administration in clinical applications. Distribution The distribution of berberine varies depending on its form and route of administration. With oral administration, tissue distribution is high, while plasma concentration is relatively low ( Tan et al., 2013 ). It particularly accumulates in the liver, adipose tissue, kidneys, and muscles. In intravenous administration, tissue distribution is faster ( Liu et al., 2010 ). While this is desirable in acute conditions, it is not practical for chronic use. Intraperitoneal administration offers higher bioavailability compared to the oral route, but tissue distribution is slower compared to intravenous administration. Four hours after administration, berberine levels in many tissues are about 70 times higher than in plasma ( Han et al., 2021 ). However, berberine levels remain stable in certain tissues such as the liver and muscles. Encapsulation of berberine or co-administration with P-glycoprotein inhibitors enhances its absorption and improves tissue distribution ( Imenshahidi & Hosseinzadeh, 2019 ; Liu et al., 2010 ). Metabolism Berberine administered orally undergoes primary metabolism in the liver and intestines. The liver enzymes responsible for metabolizing berberine include cytochrome (CY) P2D6 and CYP1A2 subtypes of CYP450 ( Fig. 1 ) ( Li et al., 2011 ). In vivo studies showed that the primary metabolic pathways of berberine include demethylation, demethylenation, reduction, and hydroxylation ( Liu et al., 2009 ). These processes lead to phase 1 metabolites of berberine. Phase 2 metabolites form through the conjugation of these metabolites with sulfuric acid or glucuronic acid. 10.7717/peerj.18924/fig-1 Figure 1 Metabolism of berberine in the liver. Berberine also undergoes metabolism in the intestines, where its structure and content can be altered by intestinal flora ( Han et al., 2021 ). This alteration occurs through demethoxylation and hydrogenation pathways, involving nitroreductases produced by intestinal flora. Dihydroberberine, a form that can be absorbed in the intestines, is produced through hydrogenation. After absorption, this form oxidizes back to berberine and enters circulation ( Han et al., 2021 ). Berberine is metabolized into four primary metabolites: berberrubine, thalifendine, demethyleneberberine, and jatrorrhizine ( Hu et al., 2018 ). After oral ingestion, berberine is distributed throughout the body, including the small intestine (undergoing presystemic elimination), liver (where it accumulates), kidneys, muscles, heart, and pancreas. The primary metabolic pathways include oxidative demethylation leading to the production of berberrubine, followed by glucuronidation. After intravenous administration, berberine undergoes oxidative demethylation, resulting in the production of demethyleneberberine, followed by glucuronidation of demethyleneberberine ( Hu et al., 2018 ). Excretion Berberine is primarily excreted via urine, feces, and bile ( Ma et al., 2013 ). Due to enterohepatic circulation, excretion via bile is slow. The excretion of berberine varies depending on the route of administration ( Han et al., 2021 ). In rats, oral or gavage administration of berberine results in feces being the primary route of excretion, with the excreted form remaining unchanged as berberine ( Feng et al., 2020 ). Excretion via urine and bile is minimal and primarily in the form of berberine metabolites. Intravenous administration of berberine shows urine as the primary excretion route ( Feng et al., 2020 ). Types of adipose tissue and browning Adipose tissue consists of white adipose tissue (WAT) and BAT, composed mainly of white and brown adipocytes, respectively ( Kurylowicz & Puzianowska-Kuznicka, 2020 ). The origins, morphologies, anatomical locations, and nearly all functions of these two types are different from each other ( Table 1 ). White adipocytes consist of a single large lipid droplet with a non-centrally located nucleus, and very few mitochondria ( Bargut et al., 2017 ). Brown adipocytes contain many small lipid droplets, have a centrally located nucleus and are dark in color due to the high number of mitochondria. Adipocyte precursor cells, also known as adipose stem cells, can differentiate into white, beige, or brown adipocytes ( Xue et al., 2015b ). The expression of myogenic factor-5 determines the difference between white and brown adipocytes. Myogenic factor-5 is associated with thermogenic activities and present in brown adipocyte precursors but not in white adipocytes ( Xue et al., 2015b ). 10.7717/peerj.18924/table-1 Table 1 Characteristics of different adipocytes. White Beige Brown Anatomical location Subcutaneous, visceral White depots and supraclavicular Interscapular, adrenal, neck Morphology Unilocular Multilocular Multilocular Lipid droplets Large Numerous and small Numerous and small Progenitor Pdgfr-α Pdgfr-α Myf5+ Main function Energy storage Thermogenesis Thermogenesis Mitochondrial biogenesis Low Medium High

Note:

Pdgfr-α, platelet-derived growth factor receptor alpha; Myf5+, myogenic factor 5-positive. White adipose tissue begins to develop during the second trimester of pregnancy, and BAT starts to develop towards the end of the second trimester ( Cypess, 2022 ). In newborns, both WAT and BAT are fully developed to perform their functions. WAT is categorized into two main types: visceral and subcutaneous and its primary function is to store energy. Energy stored in the form of triglycerides undergoes lipolysis when required, resulting in the release of fatty acids as fuel. Fifty years ago, it was thought that BAT, which was known to be present in infants, was not present in adults due to insufficient imaging techniques. With the advancement of positron emission tomographic and computed tomographic (PET/CT) imaging technique, active BAT was initially observed in the supraclavicular region of adult humans ( Cypess et al., 2009 ). Later, the presence of BAT was also identified in the neck, axillary, abdominal, and paraspinal regions in adults ( Keuper & Jastroch, 2021 ). There is a high concentration of mitochondria in brown adipocytes. Uncoupling protein 1 (UCP1) in the inner membrane of mitochondria is essential for browning and thermogenesis mechanisms ( Kurylowicz & Puzianowska-Kuznicka, 2020 ). Uncoupling protein 1 releases energy as heat instead of chemical energy by uncoupling mitochondrial respiration from adenosine triphosphate (ATP) synthesis. Therefore, it facilitates thermogenesis and promotes energy expenditure. Consequently, the identification of BAT in adults represents a promising avenue for combating the obesity epidemic. Additionally, “beige/brite” adipocytes are morphologically resemble white adipocytes but exhibit brown adipocyte function under adequate stimuli ( Cheng et al., 2021 ). Phytochemicals such as berberine, resveratrol, and curcumin, and dietary components like fish oil and retinoic acid, along with cold exposure, exercise, and β-adrenergic factors, stimulate beige adipocytes through a process known as “browning” ( Cheng et al., 2021 ; Okla et al., 2017 ). As browning progresses, beige adipocytes, which have a morphology similar to white adipocytes, begin to perform functions similar to brown adipocytes. As mitochondrial biogenesis and UCP1 expression increase, energy expenditure through thermogenesis will also increase. This is very important in combating obesity, which is mainly caused by an imbalance between energy intake and expenditure. The beige adipocytes lose their brown characteristics and return to the characteristics of the white adipocytes when the stimulus is removed ( Ziqubu et al., 2023 ). This process, called “whitening,” is considered the opposite of browning. It can be seen in obesity and during aging ( Graja, Gohlke & Schulz, 2019 ; Ziqubu et al., 2023 ). Energy expenditure and thermogenesis Obesity typically arises when energy intake exceeds energy expenditure ( Lin & Li, 2021 ). To prevent or treat obesity, energy intake must be reduced and/or energy expenditure must be increased. Dietary interventions are employed to reduce energy intake. To increase energy expenditure, it is crucial to understand the components of total energy expenditure. Approximately 70% comes from the resting metabolic rate, including the thermic effect of the foods, which reflects the energy used for digestion, absorption, and processing of nutrients ( Tran et al., 2022 ). Twenty percent is attributed to energy expenditure from physical activity, divided into non-exercise activity thermogenesis and exercise-induced thermogenesis. Ten percent arises from diet-induced thermogenesis, which occurs in response to excess caloric intake. Lastly, cold-induced thermogenesis is variable and involves mechanisms like shivering thermogenesis and non-shivering thermogenesis ( Saito et al., 2020 ). Among these components, diet-induced thermogenesis and non-shivering thermogenesis are primarily mediated by BAT ( Tran et al., 2022 ). This is because thermogenesis is primarily associated with mitochondria and UCP1, and BAT has a high mitochondrial content ( Van Thi-Tuong, Van Vu & Van Pham, 2023 ). An increase in BAT is expected to enhance these components and, consequently, increase overall energy expenditure. Browning mechanisms and bat activation There are two ways to increase thermogenesis through adipose tissue. The first is to increase browning and the second is to increase the already existing BAT activation. Browning can occur in two ways ( Kurylowicz & Puzianowska-Kuznicka, 2020 ). The first is by differentiating from precursor/stem cells and the second is by transdifferentiating from mature adipocytes. Subcutaneous adipocytes are more likely to brown than visceral adipocytes due to their ability to differentiate ( Gustafson & Smith, 2015 ). Beta-adrenergic receptor activation is considered a key stimulus for browning. The receptors involved in this system may vary between species. For example, in rodents, the β-3 adrenergic receptor (β3-AR) is involved in browning, whereas in humans the β2-AR is involved ( Blondin et al., 2020 ). Cold exposure, similar to β-adrenergic agonists, activates the sympathetic nervous system and releases norepinephrine. When the β-adrenergic receptor is stimulated, it activates cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Protein kinase A activates cAMP response element-binding protein (CREB), p38 mitogen-activated protein kinase (p38-MAPK), and mechanistic target of rapamycin (mTOR) phosphorylation. cAMP response element-binding protein and p38-MAPK increase the transcription of peroxisome proliferator-activated receptor γ-co-activator-1α (PGC-1α), which activates transcription factors that induce mitochondrial biogenesis ( Deng et al., 2019 ). Mechanistic target of rapamycin is also important for mitochondrial biogenesis ( Wei et al., 2015 ). Sympathetic activation is central to the complex mechanisms that lead to mitochondrial biogenesis, browning, and thermogenesis. Current research highlights several stimuli that enhance these processes, including exercise, specific dietary components, and pharmacological agents. For instance, exercise stimulates the production and release of irisin, which activates the p38-MAPK and extracellular signal-regulated kinase (ERK) pathways, thereby increasing UCP1 expression ( Zhang et al., 2014b ). Exercise also increases the expression of fibroblast growth factor-21 (FGF21) in the liver and adipose tissue. Its increase in adipose tissue induces UCP1 expression in white adipocytes ( Reilly et al., 2021 ). Additionally, exercise-induced reactive oxygen species (ROS) and its effects on the nervous system also play a role in adipose tissue browning ( Mu et al., 2021 ). Chronic administration of β-adrenergic agonists and leptin increases sympathetic innervation and stimulates thermogenesis ( Jimenez et al., 2003 ; Wang et al., 2020 ). Other factors also play a role in promoting browning. For example, the lipid-lowering agent fenofibrate increases thermogenesis by activating peroxisome proliferator-activated receptor (PPAR)-α ( Rachid et al., 2015 ). Similarly, PPAR agonists, agents that activate the Adenosine monophosphate (AMP)-activated protein kinase (AMPK) pathway, and substances such as nicotine (but not smoking) can stimulate browning by promoting mitochondrial biogenesis ( Gaidhu et al., 2009 ; Yoshida et al., 1999 ). Examining the expression and/or protein levels of transcription factors is one of the primary methods used to assess browning. These factors interact with each other, influencing adipogenesis and browning ( Table 2 ). Among these markers, UCP1 is considered a definitive indicator of browning and thermogenic activity. Uncoupling protein 1 activity is regulated by free fatty acids, which enhance its activity, and purine nucleotides, which inhibit it ( Macher et al., 2018 ). Which regulatory protein binds to the gene determines the transcriptional regulation of UCP1 ( Villarroya, Peyrou & Giralt, 2017 ). In the absence of UCP1, lipogenesis and liver steatosis increase ( Winn et al., 2017 ). 10.7717/peerj.18924/table-2 Table 2 Some transcription factors in browning. Transcription factor Role in browning/thermogenesis Interactions UCP1 Key marker of browning and thermogenesis. Activates heat production in adipocytes. Regulated by free fatty acids (activates) and purine nucleotides (inhibits). Transcription regulated by various factors ( e.g ., PRDM16, PPARγ) ( Macher et al., 2018 ; Jash et al., 2019 ). PPARγ Regulates both fat and carbohydrate metabolism. Plays a role in adipogenesis and lipid storage. Can induce browning under certain conditions. Interacts with LXR and RIP140 to downregulate UCP1. Agonists increase insulin sensitivity and browning but can also increase adiposity ( Machado et al., 2022 ; Wang et al., 2008 ). PGC-1α Key factor for mitochondrial biogenesis. Stimulates thermogenesis in muscle and brown adipocytes. Activated by β-adrenergic receptor stimulation. Regulates UCP1 and other thermogenic genes. Stimulated by exercise, cold, and pharmacological agents ( Deng et al., 2019 ; Ishibashi & Seale, 2015 ). CIDEA Prevents downregulation of UCP1, thus promoting browning and thermogenesis. Inhibits LXR to prevent UCP1 downregulation ( Jash et al., 2019 ). PRDM16 Activates thermogenic genes in WAT. Essential for the browning of subcutaneous WAT. Stimulates PGC-1α expression and is necessary for maintaining beige adipocytes. Low PRDM16 expression can reverse browning ( Harms et al., 2014 ; Ishibashi & Seale, 2015 ).

Note:

CIDEA, Cell Death-Inducing DNA Fragmentation Factor-Like Effector A; LXR, Liver X receptor; PGC-1α, Peroxisome Proliferator-Activated Receptor γ Co-Activator 1α; PPARγ, Peroxisome Proliferator-Activated Receptor γ; PRDM16, PR Domain Containing 16; RIP140, receptor-interacting protein 140; UCP1, Uncoupling Protein 1; WAT, white adipose tissue. PPARγ-co-activator-1α is one of the most effective factors in stimulating mitochondrial biogenesis in both muscle and brown adipocytes ( Deng et al., 2019 ). Another important browning factor is cell death-inducing DNA fragmentation factor-like effector A (CIDEA), which prevents the downregulation of UCP1 by inhibiting liver X receptors (LXRs) ( Jash et al., 2019 ). PR domain containing 16 (PRDM16) can activate thermogenic genes in WAT ( Ishibashi & Seale, 2015 ). It activates PGC-1α and is necessary for the browning of subcutaneous WAT. Low expression of PRDM16 can reverse browning and convert beige adipocytes back to white adipocytes ( Harms et al., 2014 ). PR domain containing 16 is thus critical for maintaining beige adipocytes and their thermogenic activity. Peroxisome proliferator-activated receptor-γ is another key transcription factor, influencing both fat and carbohydrate metabolism. It interacts with LXR and receptor-interacting protein 140 (RIP140) to downregulate UCP1 ( Wang et al., 2008 ). Applying PPARγ agonists can increase insulin sensitivity and browning but may also increase visceral adiposity and unwanted body weight ( Machado et al., 2022 ). Therefore, PPARγ plays a crucial role in both browning and whitening processes. Cold exposure increases browning partly by enhancing noradrenergic stimulation, which increases iodothyronine deiodinase-2 (DIO2), converting thyroxin (T4) to triiodothyronine (T3) ( Kurylowicz & Puzianowska-Kuznicka, 2020 ). Elevated T3 levels stimulate the sympathetic nervous system, thereby increasing UCP1 expression. Fibroblast growth factor-21 increases UCP1 expression by upregulating PGC-1α ( Fisher et al., 2012 ). It also enhances browning by increasing intracellular Ca ++ levels. Forkhead box C2 (FoxC2), which is expressed in adipose tissue, mediates a thermogenic effect via the PKA pathway by increasing the expression of PGC-1α and UCP1 ( Kajimura, Seale & Spiegelman, 2010 ). Both browning and the activation of brown adipose tissue are triggered by similar stimuli ( Kurylowicz & Puzianowska-Kuznicka, 2020 ). The method used to determine BAT activation is 2-deoxy-2-[ 18 F] fluoro-D-glucose ([ 18 F]FDG)-PET/CT imaging. This imaging technique allows for the tracking of the presence and size of brown adipose tissue ( van der Lans et al., 2014 ). Effects of berberine on browning and bat activation A significant portion of berberine’s effects on browning and BAT activation occurs via the AMPK pathway. Beyond this long-studied area, new pathways are being explored, with recent attention on growth differentiation factor 15 (GDF15). The effects of berberine on brown adipose tissue are shown in Fig. 2 . Studies investigating the effects of berberine on browning are summarized in Table 3 . 10.7717/peerj.18924/fig-2 Figure 2 The effect of berberine on adipose tissue browning. Berberine derived from plant sources phosphorylates AMPK, inducing HSL, ATGL, LPL, and CD36, and stimulates lipolysis. Through ACC activation, it prevents CPT1 inhibition. By increasing FGF21 expression, it enhances binding to the FGFR1c receptor. These interactions, which result in increased lipolysis and fatty acids, initiate a mechanism that leads to thermogenesis with UCP1. During inadequate energy intake, LKB1 activates AMPK, which phosphorylates RAPTOR and TSC2, suppressing mTOR (negative impact on BAT activation). By stimulating PGC1α, it plays a crucial role in browning. Independently of AMPK, berberine increases GDF15, promoting its binding to the GFRAL receptor. GFRAL stimulates appetite-related neuropeptides and the TGF- β R in the hypothalamus. The TGF-β R is a regulator of precursor cells that promote browning. Abbreviations: ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; ATGL, adipose triglyceride lipase; BAT, brown adipose tissue; CD36, cluster of differentiation 36; CPT1, carnitine palmitoyltransferase 1; FGF21, fibroblast growth factor 21; FGFR1c, fibroblast growth factor receptor 1c; GDF15, Growth differentiation factor 15; GFRAL, glial cell-derived neurotrophic factor family receptor alpha-like; HSL, hormone sensitive lipase; LKB1, liver kinase B1; mTOR, mechanistic target of rapamycin; LPL, lipoprotein lipase; PGC1α, PPARγ-co-activator-1α; RAPTOR, regulatory-associated protein of mTOR; TGF- β R, transforming growth factor β receptors; TSC2, tuberous sclerosis complex 2; UCP1, uncoupling protein 1. Created with BioRender.com. 10.7717/peerj.18924/table-3 Table 3 Studies investigating the effects of berberine on browning. Dose Duration Suggested Pathway Results References 3T3-L1 preadipocytes 0.5, 1, 5, 10 µM 7 days cAMP/PKA Adipogenic genes (C/EBP-α, PPARγ) ↓, CREB activity↓

Zhang et al. (2015) HepG2 cells 5, 10, 15 µM N/A AMPK AMPK phosphorylation↑, ACC↑, fatty acid oxidation↑

Brusq et al. (2006) Male Syrian golden hamsters 100 mg/kg/day 10 days Male C57BL/6J mice 50 and 100 mg/kg/day 14 days GDF15 Serum GDF15↑, GFRAL↑, appetite↓, UCP1↑

Li et al. (2023) Obese C57BLKS/J-Lepr db /Lepr db male mice and wild-type mice 5 mg/kg/day 4 weeks AMPK- PGC1α Energy expenditure↑, weight gain↓, BAT activity↑, UCP1↑, PGC-1α↑, CIDEA↑

Zhang et al. (2014c) Male C57BL/6J mice 100 mg/kg/day 10 weeks AMPK AMPK↑, complex I↓, AMP/ATP↑, ADP/ATP↑

Turner et al. (2008) Male Wistar rats 4 weeks Female Sprague-Dawley rats 380 mg/kg/day 2 weeks N/A Olanzapine-induce BAT loss↓, weight gain↓, adiposity↓, AMPK↑, UCP1↑, PGC1α↑. Food intake did not change.

Hu et al. (2014) Male C57BL/6J mice 25 and 100 mg/kg/day 12 weeks AMPK-SIRT1 Distribution of BAT↑, thermogenesis↑, body weight↓, AMPK/SIRT1 activation↑, PPAR↑ deacetylation↑, UCP1 expression↑

Xu et al. (2021) Obese C57BLKS/J-Lepr db /Lepr db male mice 5 mg/kg/day 26 days AMPK Lipogenesis (FAS, PPARγ)↓, expression of browning markers (PGC1α)↑, AMPK activation↑, body weight↓. Food intake did not change.

Lee et al. (2006) Wistar rats 380 mg/kg/day 2 weeks Female Sprague-Dawley rats 380 mg/kg/day 2 weeks N/A Blood lipid levels↓, weight loss↑

Hu et al. (2012) Obese humans 1.5 g/day 12 weeks Male C57BL/6J mice 1.5 mg/kg/day 6 weeks AMPK–PRDM16 Both in mice and humans: Brown adipocyte differentiation↑, PRDM16 transcription↑In mice: thermogenesis↑, energy expenditure↑AMPK is essential for the browning effect of berberine.

Wu et al. (2019) NAFLD patients 1.5 g/day 1 month Note:

ACC, acetyl-CoA carboxylase; ADP, adenosine diphosphate; AMP, adenosine monophosphate; AMPK, AMP-activated protein kinase; ATP, adenosine triphosphate; BAT, brown adipose tissue; cAMP, cyclic adenosine monophosphate; C/EBP-α, CCAAT/enhancer-binding protein alpha; CIDEA, cell death-inducing DNA fragmentation factor-like effector A; CREB, cAMP response element-binding protein; FAS, fatty acid synthetase; GDF15, Growth differentiation factor 15; GFRAL, glial cell-derived neurotrophic factor family receptor alpha-like; PGC1α, PPARγ-co-activator-1α; PKA, protein kinase A; PPARγ, Peroxisome proliferator-activated receptor-γ; PRDM16, PR domain containing 16; SIRT1, Sirtuin 1; UCP1, uncoupling protein 1. Adenosine monophosphate-activated protein kinase AMP-activated protein kinase, a serine/threonine kinase, is one of the key regulators of energy metabolism ( Wu & Zou, 2020 ). Especially in critical situations such as insufficient energy intake, it binds to adenosine diphosphate (ADP) or AMP and regulates key enzymes and proteins in carbohydrate, protein, and lipid metabolism. One of its important targets is PGC1α, which plays a role in mitochondrial homeostasis by converting type IIb muscle fibers into type I and type II fibers that contain more mitochondria ( Jager et al., 2007 ). AMP-activated protein kinase is one of the important factors regulating mitochondrial biogenesis in adipocytes and other tissues ( Yang et al., 2016 ). Mitochondrial biogenesis ensures the production of ATP that meets the increased energy expenditure. Through these mechanisms, AMPK ensures energy homeostasis by increasing ATP production and/or reducing its consumption ( van der Vaart, Boon & Houtkooper, 2021 ). The activation of AMPK is linked to browning in adipose tissue. When factors stimulating the beta-adrenergic receptor decrease, BAT activation is reduced, leading to decreased AMPK phosphorylation in BAT. AMP-activated protein kinase is influenced by triggers that activate the beta-adrenergic system, such as cold exposure ( Mulligan et al., 2007 ). Lipases play an important role in linking AMPK to brown adipose tissue activation/browning ( van der Vaart, Boon & Houtkooper, 2021 ). AMP-activated protein kinase increases the phosphorylation of hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), regulates lipoprotein lipase (LPL) and cluster of differentiation 36 (CD36), and stimulates acetyl-CoA carboxylase (ACC) to remove the suppression of carnitine palmitoyltransferase 1 (CPT1). All these actions lead to an increase in fatty acids or their entry into the mitochondria. The fatty acids bind to UCP1, inducing thermogenesis. It also increases UCP1 expression by enhancing PPARγ deacetylation through the AMPK/Sirtuin 1 (SIRT1) pathway ( Xu et al., 2021 ). In addition to activating UCP1, AMPK also stimulates PRDM16 and PPARγ by reducing isocitrate dehydrogenase 2 (IDH2) and α-ketoglutarate ( Yang et al., 2016 ). Furthermore, berberine increases FGF21 expression via the AMPK pathway, enhancing binding to the FGFR1c receptor. This stimulates both lipolysis and the activation of PGC1α and UCP1 ( Fisher et al., 2012 ; Hirai et al., 2019 ). When energy intake is limited, liver kinase B1 (LKB1) is activated and upregulates AMPK ( Agarwal et al., 2015 ). AMP-activated protein kinase phosphorylates regulatory-associated protein of mTOR (RAPTOR) and tuberous sclerosis complex 2 (TSC2), thereby suppressing mTOR. For brown adipocyte differentiation, mTOR is crucial. Therefore, it can be inferred that the activation of AMPK does not have a positive effect on BAT development. However, AMPK is important in regulating browning ( Perdikari et al., 2018 ). This is indicated by the inability to brown in the absence of AMPK. AMP-activated protein deficiency prevents brown adipocyte maturation, with the key subunit involved being AMPK-α1 ( Perdikari et al., 2017 ). However, α2 or combined knockdown of other subunits (β1, β2, γ1, and γ3) also prevents browning by reducing UCP1. While studies are showing that berberine is an activator of AMPK, it has been shown specifically to bind to the γ-subunit and activate the AMPK-α-ketoglutarate-PRDM16 pathway ( Garcia & Shaw, 2017 ; Hardie, 2013 ; Wu et al., 2019 ). Other mechanisms include the activation of AMPK by berberine through inhibition of complex I, thereby increasing the AMP:ATP and ADP:ATP ratios ( Turner et al., 2008 ). Growth differentiation factor 15 Growth differentiation factor 15 (GDF15) is a cellular stress biomarker ( Li et al., 2023 ). Growth differentiation factor 15 expression is negatively associated with appetite and food intake in diet-induced obese mice. Some drugs, like metformin, promote weight loss by increasing GDF15 levels as one of their mechanisms of action ( Coll et al., 2020 ). GDF15 binding to its receptor, glial cell-derived neurotrophic factor family receptor alpha-like (GFRAL) leads to reduced appetite in the hypothalamus by inhibiting specific neuropeptides and transforming growth factor-β receptors (TGF-β-R) ( Wang et al., 2021 ; Yang et al., 2017 ). Transforming growth factor β receptors are regulators of precursor cells that promote browning ( Wankhade et al., 2018 ). In a recent in vitro study, berberine was shown to increase GDF15 expression in adipocytes ( Li et al., 2023 ). Subsequently, when berberine was administered by gavage to obese mice, the circulating levels of GDF15 increased, appetite and food intake decreased, and as a result, the mice lost weight. Although there are studies suggesting that GDF15 can stimulate browning, thermogenesis, and energy expenditure by increasing UCP1 expression, it has also been observed that GDF15 does not affect or even downregulate UCP1 ( Choi et al., 2020 ; Chrysovergis et al., 2014 ; Li et al., 2023 ). While GDF15 secretion from adipocytes is normally quite low, berberine intake significantly increased this secretion, particularly in BAT ( Li et al., 2023 ; Wang et al., 2021 ). Although the effect of increasing GDF15 on UCP1 is not definitive, increasing BAT mass may enhance berberine-induced GDF15 secretion, thereby helping to control body weight. Future implications Berberine chloride and sulfate salts are more soluble, but the clinical use of the free form is limited due to its hydrophobic nature, low gastrointestinal absorption, and rapid metabolism. Different strategies have been developed to address the issue of low bioavailability in phytochemicals like berberine ( Li et al., 2021 ; Mirhadi, Rezaee & Malaekeh-Nikouei, 2018 ; Qiao et al., 2018 ; Yu et al., 2017 ). These methods can be broadly categorized into three main approaches. These include:

Changing the administration method (nanotechnology methods) Altering the chemical structure (organic acid salts of berberine) Co-administration with P-glycoprotein inhibitors ( e.g ., glycine, cyclosporine A) Among these methods, nanotechnology methods are the most used, especially in clinical studies. Nanoparticles are particles with diameters ranging from 10 to 1,000 nm. With these methods, particle size is reduced as much as possible, surface properties are optimized, and the biologically active material is released at an optimal level. This structure, also known as a nano-carrier, helps berberine reach target tissues while preserving its properties. Nano-carriers can include materials such as micelles, carbon-based compounds, liposomes, and polymers ( Behl et al., 2022 ). Some nanoencapsulation methods used to enhance the bioavailability of berberine are shown in Fig. 3 . 10.7717/peerj.18924/fig-3 Figure 3 Some nanoencapsulation methods to improve berberine’s bioavailability. Solid lipid nanoparticles In a system developed to increase the bioavailability of berberine and extend its duration of action, berberine is transported within solid lipid nanoparticles ( Xue et al., 2015a ). When berberine-SLN was administered orally to db/db mice, berberine was stored in the brain, liver, and jejunum. In this system, the elimination of berberine from the body was reduced, and its circulating levels were increased. Berberine encapsulated in SLNs reduced triglyceride and alanine transaminase (ALT) concentrations in the liver, and its anti-diabetic effect was enhanced through nanoencapsulation. Additionally, the presence of berberine in the brain demonstrated that SLN-encapsulated berberine could cross the blood-brain barrier. Berberine-SLN was spherical. The efficiency of encapsulation was 58%, with a loading capacity of 4.2%. The particle size measured 76.8 nm, and the zeta potential was 7.87 mV. The bioavailability of orally administered berberine-SLN (50 mg/kg body weight) was higher compared to free berberine. In the study conducted by Xue et al. (2013) , the peak plasma concentration of free berberine was reported as 11.1 ± 6.24, whereas that of berberine-SLNs was significantly higher at 44.651 ± 4.77. Similarly, the area under the curve (AUC) values were 56.5 ± 29.61 for free berberine and 113.6 ± 72.93 for berberine-SLNs, indicating a substantial improvement in bioavailability with the SLN formulation ( Xue et al., 2013 ). Berberine chloride-loaded SLNs are used in studies aimed at preventing and treating various health issues, including cancer therapy ( Wang et al., 2014 ; Xue et al., 2013 ). Nanostructured lipid carriers This nano-carrier method was developed to address the limitations of SLNs by replacing some of the solid lipids in the structure with liquid lipids. This modification increased the loading capacity and prevented berberine leakage during storage. Berberine-NLCs are also spherical, with an encapsulation efficiency of 88%, a particle size of 186 nm, a zeta potential of −36.86 mV, and a polydispersity index of 0.108. Berberine-NLC structures are frequently encountered in studies related to liver health, cognitive functions, and various tumors ( Gendy et al., 2022 ; Raju et al., 2021 ). Liposomes Liposomes are nano-carriers composed of cholesterol and phospholipids. Like other lipid-based nanoencapsulation methods, they are spherical. Due to the hydrophobic and hydrophilic properties of phospholipids, liposomes are used to deliver antibacterial, antifungal, anticancer, and anti-inflammatory drugs, as well as phytochemicals ( Akbarzadeh et al., 2013 ). The literature contains studies on the use of liposomal berberine for liver diseases, cardiovascular diseases, and certain tumors ( Allijn et al., 2017 ; Calvo et al., 2020 ; Lin et al., 2013 ). Micelles Micelles are complex structures based on surfactants that use various phosphatidylcholine mixtures. They can be spherical or resemble a disk. Encapsulating berberine in anhydrous reverse micelles (ARM) increases berberine’s oral bioavailability by 2.4 times ( Wang et al., 2011 ). Berberine-loaded micelles were found to increase berberine solubility by 800% and its absorption by 364%. Additionally, the efflux rate of berberine within the micelles decreased from 7.54 to 1.05. This indicates that the inhibition of P-glycoprotein-mediated efflux leads to an increase in the intestinal absorption of berberine ( Kwon et al., 2020 ). Dendrimers Dendrimers have a branched structure and are polymeric nano-carriers with many functional groups on their surfaces ( Sherje et al., 2018 ). Due to these characteristics, dendrimers exhibit high efficacy and bioavailability. Their unique branched structure, high solubility in water, ability to neutralize various toxins, antigens, or microorganisms, and the simplicity of their production method make them particularly useful in the field of pharmacology. Berberine encapsulated in polyamidoamine (PAMAM) dendrimers increases its permeability, enhancing its bioavailability and therapeutic effects ( An et al., 2023 ). These dendrimers are biocompatible and safe, making them suitable for use in various medical applications ( Gupta et al., 2017 ). They are commonly employed in cancer research, where they help improve drug delivery by targeting cancer cells more effectively and providing controlled release ( Yadav, Semwal & Dewangan, 2023 ). Conclusions Berberine, a herbal compound used in Asia for centuries, has recently gained attention for its health benefits, particularly in weight management. While studies generally report positive effects, the underlying mechanisms remain unclear. Key mechanisms include AMPK pathway activation, increased browning markers like UCP1, and appetite-regulating markers such as GDF15. Given the importance of adipose tissue browning and BAT activation in preventing obesity, berberine’s potential to enhance energy expenditure is critical. However, its therapeutic potential is limited by low stability and poor bioavailability. For berberine to exert its effects, it must achieve and maintain effective concentrations in circulation when taken orally. Nanotechnological approaches, which improve stability and bioavailability, represent a promising solution. Despite their benefits, these methods face challenges such as high production costs, scalability issues, and regulatory hurdles. Advances in manufacturing techniques and cost-reduction strategies are essential for integrating nanotechnology-based therapies into routine clinical practice. Future research should focus on developing new methods suitable for oral administration that enhance encapsulation efficiency and loading capacity. Additional clinical trials are needed to address the low bioavailability and insufficient toxicity data, which currently prevent the U.S. Food and Drug Administration (FDA) from classifying berberine as a drug. Comprehensive studies in diverse populations are crucial to fully establish berberine’s efficacy, optimal dosage, and clinical application. Additional Information and Declarations Competing Interests The authors declare that they have no competing interests. Author Contributions Aslıhan Alpaslan Ağaçdiken conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft. Zeynep Göktaş conceived and designed the experiments, performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft. Data Availability The following information was supplied regarding data availability: This is a literature review. References Agarwal et al. (2015)

Agarwal S Bell CM Rothbart SB Moran RG AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in pemetrexed-treated carcinoma cells Journal of Biological Chemistry 2015 290 46 27473 27486 10.1074/jbc.M115.665133 26391395 PMC4646000 Akbarzadeh et al. (2013)

Akbarzadeh A Rezaei-Sadabady R Davaran S Joo SW Zarghami N

Hanifehpour Y Samiei M Kouhi M Nejati-Koshki K Liposome: classification, preparation, and applications Nanoscale Research Letters 2013 8 102 10.1186/1556-276X-8-102 23432972 PMC3599573 Allijn et al. (2017)

Allijn IE Czarny BMS Wang X Chong SY Weiler M da Silva AE

Metselaar JM Lam CSP Pastorin G de Kleijn DPV Storm G

Wang JW Schiffelers RM Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction Journal of Controlled Release 2017 247 127 133 10.1016/j.jconrel.2016.12.042 28065862 An et al. (2023)

An H Deng X Wang F Xu P Wang N Dendrimers as nanocarriers for the delivery of drugs obtained from natural products Polymers (Basel) 2023 15 10 2292 10.3390/polym15102292 37242865 PMC10221236 Bargut et al. (2017)

Bargut TCL Souza-Mello V Aguila MB Mandarim-de-Lacerda CA

Browning of white adipose tissue: lessons from experimental models Hormone Molecular Biology and Clinical Investigation 2017 31 e0051 10.1515/hmbci-2016-0051 28099124 Behl et al. (2022)

Behl T Singh S Sharma N Zahoor I Albarrati A Albratty M

Meraya AM Najmi A Bungau S Expatiating the pharmacological and nanotechnological aspects of the alkaloidal drug berberine: current and future trends Molecules 2022 27 12 3705 10.3390/molecules27123705 35744831 PMC9229453 Blondin et al. (2020)

Blondin DP Nielsen S Kuipers EN Severinsen MC Jensen VH

Miard S Jespersen NZ Kooijman S Boon MR Fortin M Phoenix S

Frisch F Guerin B Turcotte EE Haman F Richard D Picard F

Rensen PCN Scheele C Carpentier AC Human brown adipocyte thermogenesis is driven by beta2-AR stimulation Cell Metabolism 2020 32 2 287 300 10.1016/j.cmet.2020.07.005 32755608 Brusq et al. (2006)

Brusq JM Ancellin N Grondin P Guillard R Martin S Saintillan Y

Issandou M Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine Journal of Lipid Research 2006 47 6 1281 1288 10.1194/jlr.M600020-JLR200 16508037 Calvo et al. (2020)

Calvo A Moreno E Larrea E Sanmartin C Irache JM Espuelas S

Berberine-loaded liposomes for the treatment of leishmania infantum -infected BALB/c mice Pharmaceutics 2020 12 9 858 10.3390/pharmaceutics12090858 32916948 PMC7558179 Cheng et al. (2021)

Cheng L Wang J Dai H Duan Y An Y Shi L Lv Y Li H Wang C

Ma Q Li Y Li P Du H Zhao B Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus Adipocyte 2021 10 48 65 10.1080/21623945.2020.1870060 33403891 PMC7801117 Choi et al. (2020)

Choi MJ Jung SB Lee SE Kang SG Lee JH Ryu MJ Chung HK

Chang JY Kim YK Hong HJ Kim H Kim HJ Lee CH Mardinoglu A

Yi HS Shong M An adipocyte-specific defect in oxidative phosphorylation increases systemic energy expenditure and protects against diet-induced obesity in mouse models Diabetologia 2020 63 4 837 852 10.1007/s00125-019-05082-7 31925461 Chrysovergis et al. (2014)

Chrysovergis K Wang X Kosak J Lee SH Kim JS Foley JF

Travlos G Singh S Baek SJ Eling TE NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism International Journal of Obesity 2014 38 12 1555 1564 10.1038/ijo.2014.27 24531647 PMC4135041 Coll et al. (2020)

Coll AP Chen M Taskar P Rimmington D Patel S Tadross JA

Cimino I Yang M Welsh P Virtue S Goldspink DA Miedzybrodzka EL

Konopka AR Esponda RR Huang JT Tung YCL Rodriguez-Cuenca S

Tomaz RA Harding HP Melvin A Yeo GSH Preiss D Vidal-Puig A

Vallier L Nair KS Wareham NJ Ron D Gribble FM Reimann F

Sattar N Savage DB Allan BB O’Rahilly S GDF15 mediates the effects of metformin on body weight and energy balance Nature 2020 578 7795 444 448 10.1038/s41586-019-1911-y 31875646 PMC7234839 Cypess (2022)

Cypess AM Reassessing human adipose tissue New England Journal of Medicine 2022 386 8 768 779 10.1056/NEJMra2032804 35196429 Cypess et al. (2009)

Cypess AM Lehman S Williams G Tal I Rodman D Goldfine AB

Kuo FC Palmer EL Tseng YH Doria A Kolodny GM Kahn CR

Identification and importance of brown adipose tissue in adult humans New England Journal of Medicine 2009 360 15 1509 1517 10.1056/NEJMoa0810780 19357406 PMC2859951 Deng et al. (2019)

Deng X Zhang S Wu J Sun X Shen Z Dong J Huang J Promotion of mitochondrial biogenesis via activation of AMPK-PGC1a signaling pathway by Ginger ( Zingiber officinale Roscoe ) extract, and its major active component 6-Gingerol Journal of Food Science 2019 84 8 2101 2111 10.1111/1750-3841.14723 31369153 Feng et al. (2019)

Feng X Sureda A Jafari S Memariani Z Tewari D Annunziata G

Barrea L Hassan STS Smejkal K Malanik M Sychrova A

Barreca D Ziberna L Mahomoodally MF Zengin G Xu S Nabavi SM

Shen AZ Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics Theranostics 2019 9 7 1923 1951 10.7150/thno.30787 31037148 PMC6485276 Feng et al. (2020)

Feng X Wang K Cao S Ding L Qiu F Pharmacokinetics and excretion of berberine and its nine metabolites in rats Frontiers in Pharmacology 2020 11 594852 10.3389/fphar.2020.594852 33584274 PMC7874128 Fisher et al. (2012)

Fisher FM Kleiner S Douris N Fox EC Mepani RJ Verdeguer F

Wu J Kharitonenkov A Flier JS Maratos-Flier E Spiegelman BM

FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis Genes & Development 2012 26 3 271 281 10.1101/gad.177857.111 22302939 PMC3278894 Gaidhu et al. (2009)

Gaidhu MP Fediuc S Anthony NM So M Mirpourian M Perry RL

Ceddia RB Prolonged AICAR-induced AMP-kinase activation promotes energy dissipation in white adipocytes: novel mechanisms integrating HSL and ATGL Journal of Lipid Research 2009 50 4 704 715 10.1194/jlr.M800480-JLR200 19050316 PMC2656664 Garcia & Shaw (2017)

Garcia D Shaw RJ AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance Molecular Cell 2017 66 6 789 800 10.1016/j.molcel.2017.05.032 28622524 PMC5553560 Gendy et al. (2022)

Gendy AM Elnagar MR Allam MM Mousa MR Khodir AE El-Haddad AE

Elnahas OS Fayez SM El-Mancy SS Berberine-loaded nanostructured lipid carriers mitigate warm hepatic ischemia/reperfusion-induced lesion through modulation of HMGB1/TLR4/NF-kappaB signaling and autophagy Biomedicine & Pharmacotherapy 2022 145 112122 10.1016/j.biopha.2021.112122 34489150 Graja, Gohlke & Schulz (2019)

Graja A Gohlke S Schulz TJ Aging of brown and beige/brite adipose tissue Handbook of Experimental Pharmacology 2019 251 55 72 10.1007/978-3-030-10513-6 30141100 Gupta et al. (2017)

Gupta L Sharma AK Gothwal A Khan MS Khinchi MP Qayum A

Singh SK Gupta U Dendrimer encapsulated and conjugated delivery of berberine: a novel approach mitigating toxicity and improving in vivo pharmacokinetics International Journal of Pharmaceutics 2017 528 1–2 88 99 10.1016/j.ijpharm.2017.04.073 28533175 Gustafson & Smith (2015)

Gustafson B Smith U Regulation of white adipogenesis and its relation to ectopic fat accumulation and cardiovascular risk Atherosclerosis 2015 241 1 27 35 10.1016/j.atherosclerosis.2015.04.812 25957567 Habtemariam (2020)

Habtemariam S Berberine pharmacology and the gut microbiota: a hidden therapeutic link Pharmacological Research 2020 155 5 104722 10.1016/j.phrs.2020.104722 32105754 Han et al. (2021)

Han Y Xiang Y Shi Y Tang X Pan L Gao J Bi R Lai X Pharmacokinetics and pharmacological activities of berberine in diabetes mellitus treatment Evidence-Based Complementary and Alternative Medicine 2021 2021 1 1 15 10.1155/2021/9987097 PMC8405293 34471420 Hardie (2013)

Hardie DG AMPK: a target for drugs and natural products with effects on both diabetes and cancer Diabetes 2013 62 7 2164 2172 10.2337/db13-0368 23801715 PMC3712072 Harms et al. (2014)

Harms MJ Ishibashi J Wang W Lim HW Goyama S Sato T

Kurokawa M Won KJ Seale P Prdm16 is required for the maintenance of brown adipocyte identity and function in adult mice Cell Metabolism 2014 19 4 593 604 10.1016/j.cmet.2014.03.007 24703692 PMC4012340 Hesari et al. (2018)

Hesari A Ghasemi F Cicero AFG Mohajeri M Rezaei O Hayat SMG

Sahebkar A Berberine: a potential adjunct for the treatment of gastrointestinal cancers? Journal of Cellular Biochemistry 2018 119 12 9655 9663 10.1002/jcb.27392 30125974 Hirai et al. (2019)

Hirai T Mitani Y Kurumisawa K Nomura K Wang W Nakashima KI

Inoue M Berberine stimulates fibroblast growth factor 21 by modulating the molecular clock component brain and muscle Arnt-like 1 in brown adipose tissue Biochemical Pharmacology 2019 164 1 165 176 10.1016/j.bcp.2019.04.017 30991048 Hu et al. (2012)

Hu Y Ehli EA Kittelsrud J Ronan PJ Munger K Downey T

Bohlen K Callahan L Munson V Jahnke M Marshall LL Nelson K

Huizenga P Hansen R Soundy TJ Davies GE Lipid-lowering effect of berberine in human subjects and rats Phytomedicine 2012 19 10 861 867 10.1016/j.phymed.2012.05.009 22739410 Hu et al. (2014)

Hu Y Young AJ Ehli EA Nowotny D Davies PS Droke EA

Soundy TJ Davies GE Metformin and berberine prevent olanzapine-induced weight gain in rats PLOS ONE 2014 9 3 e93310 10.1371/journal.pone.0093310 24667776 PMC3965561 Hu et al. (2018)

Hu X Zhang Y Xue Y Zhang Z Wang J Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation American Journal of Translational Research 2018 10 3322 3329 30662589 PMC6291723 Ilyas et al. (2020)

Ilyas Z Perna S Al-Thawadi S Alalwan TA Riva A Petrangolini G

Gasparri C Infantino V Peroni G Rondanelli M The effect of Berberine on weight loss in order to prevent obesity: a systematic review Biomedicine & Pharmacotherapy 2020 127 7 110137 10.1016/j.biopha.2020.110137 32353823 Imenshahidi & Hosseinzadeh (2019)

Imenshahidi M Hosseinzadeh H Berberine and barberry (Berberis vulgaris): a clinical review Phytotherapy Research 2019 33 3 504 523 10.1002/ptr.6252 30637820 Ishibashi & Seale (2015)

Ishibashi J Seale P Functions of Prdm16 in thermogenic fat cells Temperature (Austin) 2015 2 1 65 72 10.4161/23328940.2014.974444 27227007 PMC4843880 Jager et al. (2007)

Jager S Handschin C St-Pierre J Spiegelman BM AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha Proceedings of the National Academy of Sciences of the United States of America 2007 104 29 12017 12022 10.1073/pnas.0705070104 17609368 PMC1924552 Jash et al. (2019)

Jash S Banerjee S Lee MJ Farmer SR Puri V CIDEA transcriptionally regulates UCP1 for britening and thermogenesis in human fat cells iScience 2019 20 73 89 10.1016/j.isci.2019.09.011 31563853 PMC6817690 Jimenez et al. (2003)

Jimenez M Barbatelli G Allevi R Cinti S Seydoux J Giacobino JP

Muzzin P Preitner F Beta 3-adrenoceptor knockout in C57BL/6J mice depresses the occurrence of brown adipocytes in white fat European Journal of Biochemistry 2003 270 4 699 705 10.1046/j.1432-1033.2003.03422.x 12581209 Kajimura, Seale & Spiegelman (2010)

Kajimura S Seale P Spiegelman BM Transcriptional control of brown fat development Cell Metabolism 2010 11 4 257 262 10.1016/j.cmet.2010.03.005 20374957 PMC2857670 Keuper & Jastroch (2021)

Keuper M Jastroch M The good and the BAT of metabolic sex differences in thermogenic human adipose tissue Molecular and Cellular Endocrinology 2021 533 18 111337 10.1016/j.mce.2021.111337 34062167 Kurylowicz & Puzianowska-Kuznicka (2020)

Kurylowicz A Puzianowska-Kuznicka M Induction of adipose tissue browning as a strategy to combat obesity International Journal of Molecular Sciences 2020 21 17 6241 10.3390/ijms21176241 32872317 PMC7504355 Kwon et al. (2020)

Kwon M Lim DY Lee CH Jeon JH Choi MK Song IS Enhanced intestinal absorption and pharmacokinetic modulation of berberine and its metabolites through the inhibition of P-Glycoprotein and Intestinal metabolism in rats using a berberine mixed micelle formulation Pharmaceutics 2020 12 9 882 10.3390/pharmaceutics12090882 32957491 PMC7558015 Lee et al. (2006)

Lee YS Kim WS Kim KH Yoon MJ Cho HJ Shen Y Ye JM Lee CH

Oh WK Kim CT Hohnen-Behrens C Gosby A Kraegen EW James DE

Kim JB Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states Diabetes 2006 55 8 2256 2264 10.2337/db06-0006 16873688 Li et al. (2023)

Li C Leng Q Li L Hu F Xu Y Gong S Yang Y Zhang H Li X

Berberine ameliorates obesity by inducing GDF15 secretion by brown adipocytes Endocrinology 2023 164 4 253 10.1210/endocr/bqad035 36825874 Li et al. (2011)

Li Y Ren G Wang YX Kong WJ Yang P Wang YM Li YH Yi H

Li ZR Song DQ Jiang JD Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes Journal of Translational Medicine 2011 9 62 10.1186/1479-5876-9-62 21569619 PMC3103436 Li et al. (2021)

Li DD Yu P Xu H Wang ZZ Xiao W Zhao LG Discovery of C-9 modified berberine derivatives as novel lipid-lowering agents Chemical and Pharmaceutical Bulletin 2021 69 1 59 66 10.1248/cpb.c20-00453 33087641 Lin et al. (2013)

Lin YC Kuo JY Hsu CC Tsai WC Li WC Yu MC Wen HW Optimizing manufacture of liposomal berberine with evaluation of its antihepatoma effects in a murine xenograft model International Journal of Pharmaceutics 2013 441 1–2 381 388 10.1016/j.ijpharm.2012.11.017 23220078 Lin & Li (2021)

Lin X Li H Obesity: epidemiology, pathophysiology, and therapeutics Frontiers in Endocrinology 2021 12 706978 10.3389/fendo.2021.706978 34552557 PMC8450866 Linn et al. (2012)

Linn YC Lu J Lim LC Sun H Sun J Zhou Y Ng HS Berberine-induced haemolysis revisited: safety of Rhizoma coptidis and Cortex phellodendri in chronic haematological diseases Phytotherapy Research 2012 26 5 682 686 10.1002/ptr.3617 22002596 Liu et al. (2010)

Liu YT Hao HP Xie HG Lai L Wang Q Liu CX Wang GJ Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats Drug Metabolism and Disposition 2010 38 10 1779 1784 10.1124/dmd.110.033936 20634337 Liu et al. (2009)

Liu Y Hao H Xie H Lv H Liu C Wang G Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats Journal of Pharmaceutical Sciences 2009 98 11 4391 4401 10.1002/jps.21721 19283771 Ma et al. (2013)

Ma JY Feng R Tan XS Ma C Shou JW Fu J Huang M He CY

Chen SN Zhao ZX He WY Wang Y Jiang JD Excretion of berberine and its metabolites in oral administration in rats Journal of Pharmaceutical Sciences 2013 102 11 4181 4192 10.1002/jps.23718 24006193 Machado et al. (2022)

Machado SA Pasquarelli-do-Nascimento G da Silva DS

Farias GR de Oliveira Santos I Baptista LB Magalhaes KG

Browning of the white adipose tissue regulation: new insights into nutritional and metabolic relevance in health and diseases Nutrition & Metabolism 2022 19 61 10.1186/s12986-022-00694-0 36068578 PMC9446768 Macher et al. (2018)

Macher G Koehler M Rupprecht A Kreiter J Hinterdorfer P

Pohl EE Inhibition of mitochondrial UCP1 and UCP3 by purine nucleotides and phosphate Biochimica et Biophysica Acta (BBA) - Biomembranes 2018 1860 3 664 672 10.1016/j.bbamem.2017.12.001 29212043 PMC6118327 Marlatt & Ravussin (2017)

Marlatt KL Ravussin E Brown adipose tissue: an update on recent findings Current Obesity Reports 2017 6 4 389 396 10.1007/s13679-017-0283-6 29101739 PMC5777285 Mayoral et al. (2020)

Mayoral LP Andrade GM Mayoral EP Huerta TH Canseco SP

Rodal Canales FJ Cabrera-Fuentes HA Cruz MM Perez Santiago AD

Alpuche JJ Zenteno E Ruiz HM Cruz RM Jeronimo JH Perez-Campos E

Obesity subtypes, related biomarkers & heterogeneity Indian Journal of Medical Research 2020 151 1 11 21 10.4103/ijmr.IJMR_1768_17 32134010 PMC7055173 Mirhadi, Rezaee & Malaekeh-Nikouei (2018)

Mirhadi E Rezaee M Malaekeh-Nikouei B Nano strategies for berberine delivery, a natural alkaloid of Berberis Biomedicine & Pharmacotherapy 2018 104 2 465 473 10.1016/j.biopha.2018.05.067 29793179 Mu et al. (2021)

Mu WJ Zhu JY Chen M Guo L Exercise-mediated browning of white adipose tissue: its significance, mechanism and effectiveness International Journal of Molecular Sciences 2021 22 21 11512 10.3390/ijms222111512 34768943 PMC8583930 Mulligan et al. (2007)

Mulligan JD Gonzalez AA Stewart AM Carey HV Saupe KW

Upregulation of AMPK during cold exposure occurs via distinct mechanisms in brown and white adipose tissue of the mouse The Journal of Physiology 2007 580 2 677 684 10.1113/jphysiol.2007.128652 17272339 PMC2075554 Okla et al. (2017)

Okla M Kim J Koehler K Chung S Dietary factors promoting brown and beige fat development and thermogenesis Advances in Nutrition 2017 8 3 473 483 10.3945/an.116.014332 28507012 PMC5421122 Park, Jung & Shim (2020)

Park HJ Jung E Shim I Berberine for appetite suppressant and prevention of obesity BioMed Research International 2020 2020 1 3891806 10.1155/2020/3891806 33415147 PMC7752296 Perdikari et al. (2017)

Perdikari A Kulenkampff E Rudigier C Neubauer H Luippold G

Redemann N Wolfrum C A high-throughput, image-based screen to identify kinases involved in brown adipocyte development Science Signaling 2017 10 466 R473 10.1126/scisignal.aaf5357 28196906 Perdikari et al. (2018)

Perdikari A Leparc GG Balaz M Pires ND Lidell ME Sun W

Fernandez-Albert F Muller S Akchiche N Dong H Balazova L

Opitz L Roder E Klein H Stefanicka P Varga L Nuutila P

Virtanen KA Niemi T Taittonen M Rudofsky G Ukropec J

Enerback S Stupka E Neubauer H Wolfrum C BATLAS: deconvoluting brown adipose tissue Cell Reports 2018 25 3 784 797 10.1016/j.celrep.2018.09.044 30332656 Pirillo & Catapano (2015)

Pirillo A Catapano AL Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies Atherosclerosis 2015 243 2 449 461 10.1016/j.atherosclerosis.2015.09.032 26520899 Qiao et al. (2018)

Qiao X Wang Q Wang S Kuang Y Li K Song W Ye M A 42-markers pharmacokinetic study reveals interactions of berberine and glycyrrhizic acid in the anti-diabetic Chinese medicine formula Gegen-Qinlian decoction Frontiers in Pharmacology 2018 9 622 10.3389/fphar.2018.00622 29971002 PMC6018403 Rachid et al. (2015)

Rachid TL Penna-de-Carvalho A Bringhenti I Aguila MB

Mandarim-de-Lacerda CA Souza-Mello V Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice Molecular and Cellular Endocrinology 2015 402 Suppl. 5 86 94 10.1016/j.mce.2014.12.027 25576856 Raju et al. (2021)

Raju M Kunde SS Auti ST Kulkarni YA Wairkar S Berberine loaded nanostructured lipid carrier for Alzheimer’s disease: design, statistical optimization and enhanced in vivo performance Life Sciences 2021 285 119990 10.1016/j.lfs.2021.119990 34592234 Reilly et al. (2021)

Reilly SM Abu-Odeh M Ameka M DeLuca JH Naber MC Dadpey B

Ebadat N Gomez AV Peng X Poirier B Walk E Potthoff MJ

Saltiel AR FGF21 is required for the metabolic benefits of IKKepsilon/TBK1 inhibition The Journal of Clinical Investigation 2021 131 10 e145546 10.1172/JCI145546 33822771 PMC8121507 Rong et al. (2021)

Rong Q Han B Li Y Yin H Li J Hou Y Berberine reduces lipid accumulation by promoting fatty acid oxidation in renal tubular epithelial cells of the diabetic kidney Frontiers in Pharmacology 2021 12 729384 10.3389/fphar.2021.729384 35069186 PMC8766852 Saito et al. (2020)

Saito M Matsushita M Yoneshiro T Okamatsu-Ogura Y Brown adipose tissue, diet-induced thermogenesis, and thermogenic food ingredients: from mice to men Front Endocrinol (Lausanne) 2020 11 222 10.3389/fendo.2020.00222 32373072 PMC7186310 Sherje et al. (2018)

Sherje AP Jadhav M Dravyakar BR Kadam D Dendrimers: a versatile nanocarrier for drug delivery and targeting International Journal of Pharmaceutics 2018 548 1 707 720 10.1016/j.ijpharm.2018.07.030 30012508 Song, Hao & Fan (2020)

Song D Hao J Fan D Biological properties and clinical applications of berberine Frontiers of Medicine 2020 14 5 564 582 10.1007/s11684-019-0724-6 32335802 Tan et al. (2013)

Tan XS Ma JY Feng R Ma C Chen WJ Sun YP Fu J Huang M

He CY Shou JW He WY Wang Y Jiang JD Tissue distribution of berberine and its metabolites after oral administration in rats PLOS ONE 2013 8 10 e77969 10.1371/journal.pone.0077969 24205048 PMC3815028 Tran et al. (2022)

Tran LT Park S Kim SK Lee JS Kim KW Kwon O Hypothalamic control of energy expenditure and thermogenesis Experimental & Molecular Medicine 2022 54 4 358 369 10.1038/s12276-022-00741-z 35301430 PMC9076616 Turner et al. (2008)

Turner N Li JY Gosby A To SW Cheng Z Miyoshi H Taketo MM

Cooney GJ Kraegen EW James DE Hu LH Li J Ye JM Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action Diabetes 2008 57 5 1414 1418 10.2337/db07-1552 18285556 van der Lans et al. (2014) van der Lans AA

Wierts R Vosselman MJ Schrauwen P Brans B van Marken Lichtenbelt WD

Cold-activated brown adipose tissue in human adults: methodological issues American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2014 307 2 R103 R113 10.1152/ajpregu.00021.2014 24871967 van der Vaart, Boon & Houtkooper (2021) van der Vaart JI

Boon MR Houtkooper RH The role of AMPK signaling in brown adipose tissue activation Cells 2021 10 5 1122 10.3390/cells10051122 34066631 PMC8148517 Van Thi-Tuong, Van Vu & Van Pham (2023)

Van Thi-Tuong N Van Vu V Van Pham P Brown adipocyte and browning thermogenesis: metabolic crosstalk beyond mitochondrial limits and physiological impacts Adipocyte 2023 12 2237164 10.1080/21623945.2023.2237164 37488770 PMC10392766 Villarroya, Peyrou & Giralt (2017)

Villarroya F Peyrou M Giralt M Transcriptional regulation of the uncoupling protein-1 gene Biochimie 2017 134 11 86 92 10.1016/j.biochi.2016.09.017 27693079 Wang et al. (2021)

Wang D Day EA Townsend LK Djordjevic D Jorgensen SB

Steinberg GR GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease Nature Reviews Endocrinology 2021 17 10 592 607 10.1038/s41574-021-00529-7 34381196 Wang et al. (2017)

Wang K Feng X Chai L Cao S Qiu F The metabolism of berberine and its contribution to the pharmacological effects Drug Metabolism Reviews 2017 49 2 139 157 10.1080/03602532.2017.1306544 28290706 Wang et al. (2014)

Wang L Li H Wang S Liu R Wu Z Wang C Wang Y Chen M

Enhancing the antitumor activity of berberine hydrochloride by solid lipid nanoparticle encapsulation AAPS PharmSciTech 2014 15 4 834 844 10.1208/s12249-014-0112-0 24696391 PMC4113611 Wang et al. (2020)

Wang P Loh KH Wu M Morgan DA Schneeberger M Yu X Chi J

Kosse C Kim D Rahmouni K Cohen P Friedman J A leptin-BDNF pathway regulating sympathetic innervation of adipose tissue Nature 2020 583 7818 839 844 10.1038/s41586-020-2527-y 32699414 Wang et al. (2011)

Wang T Wang N Song H Xi X Wang J Hao A Li T Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine European Journal of Pharmaceutical Sciences 2011 44 1–2 127 135 10.1016/j.ejps.2011.06.015 21742030 Wang et al. (2008)

Wang H Zhang Y Yehuda-Shnaidman E Medvedev AV Kumar N

Daniel KW Robidoux J Czech MP Mangelsdorf DJ Collins S

Liver X receptor alpha is a transcriptional repressor of the uncoupling protein 1 gene and the brown fat phenotype Molecular and Cellular Biology 2008 28 7 2187 2200 10.1128/MCB.01479-07 18195045 PMC2268430 Wankhade et al. (2018)

Wankhade UD Lee JH Dagur PK Yadav H Shen M Chen W Kulkarni AB

McCoy JP Finkel T Cypess AM Rane SG TGF-beta receptor 1 regulates progenitors that promote browning of white fat Molecular Metabolism 2018 16 Pt. 4 160 171 10.1016/j.molmet.2018.07.008 30100246 PMC6158128 Wei et al. (2015)

Wei Y Zhang YJ Cai Y Xu MH The role of mitochondria in mTOR-regulated longevity Biological Reviews of the Cambridge Philosophical Society 2015 90 1 167 181 10.1111/brv.12103 24673778 Winn et al. (2017)

Winn NC Vieira-Potter VJ Gastecki ML Welly RJ Scroggins RJ

Zidon TM Gaines TL Woodford ML Karasseva NG Kanaley JA

Sacks HS Padilla J Loss of UCP1 exacerbates Western diet-induced glycemic dysregulation independent of changes in body weight in female mice American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2017 312 1 R74 R84 10.1152/ajpregu.00425.2016 27881400 PMC5283932 Wu et al. (2019)

Wu L Xia M Duan Y Zhang L Jiang H Hu X Yan H Zhang Y

Gu Y Shi H Li J Gao X Li J Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans Cell Death & Disease 2019 10 6 468 10.1038/s41419-019-1706-y 31197160 PMC6565685 Wu & Zou (2020)

Wu S Zou MH AMPK, mitochondrial function, and cardiovascular disease International Journal of Molecular Sciences 2020 21 14 4987 10.3390/ijms21144987 32679729 PMC7404275 Xu et al. (2021)

Xu Y Yu T Ma G Zheng L Jiang X Yang F Wang Z Li N He Z

Song X Wen D Kong J Yu Y Cao L Berberine modulates deacetylation of PPARgamma to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway International Journal of Biological Sciences 2021 17 12 3173 3187 10.7150/ijbs.62556 34421358 PMC8375237 Xue et al. (2015b)

Xue R Lynes MD Dreyfuss JM Shamsi F Schulz TJ Zhang H

Huang TL Townsend KL Li Y Takahashi H Weiner LS White AP

Lynes MS Rubin LL Goodyear LJ Cypess AM Tseng YH Clonal analyses and gene profiling identify genetic biomarkers of the thermogenic potential of human brown and white preadipocytes Nature Medicine 2015b 21 7 760 768 10.1038/nm.3881 PMC4496292 26076036 Xue et al. (2013)

Xue M Yang MX Zhang W Li XM Gao DH Ou ZM Li ZP Liu SH

Li XJ Yang SY Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles International Journal of Nanomedicine 2013 8 4677 4687 10.2147/IJN.S51262 24353417 PMC3862509 Xue et al. (2015a)

Xue M Zhang L Yang MX Zhang W Li XM Ou ZM Li ZP Liu SH

Li XJ Yang SY Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice International Journal of Nanomedicine 2015a 10 5049 5057 10.2147/IJN 26346310 PMC4531046 Yadav, Semwal & Dewangan (2023)

Yadav D Semwal BC Dewangan HK Grafting, characterization and enhancement of therapeutic activity of berberine loaded PEGylated PAMAM dendrimer for cancerous cell Journal of Biomaterials Science, Polymer Edition 2023 34 8 1053 1066 10.1080/09205063.2022.2155782 36469754 Yang et al. (2017)

Yang L Chang CC Sun Z Madsen D Zhu H Padkjaer SB Wu X

Huang T Hultman K Paulsen SJ Wang J Bugge A Frantzen JB

Norgaard P Jeppesen JF Yang Z Secher A Chen H Li X

John LM Shan B He Z Gao X Su J Hansen KT Yang W Jorgensen SB

GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand Nature Medicine 2017 23 10 1158 1166 10.1038/nm.4394 28846099 Yang et al. (2016)

Yang Q Liang X Sun X Zhang L Fu X Rogers CJ Berim A

Zhang S Wang S Wang B Foretz M Viollet B Gang DR Rodgers BD

Zhu MJ Du M AMPK/alpha-ketoglutarate axis dynamically mediates DNA demethylation in the Prdm16 promoter and brown adipogenesis Cell Metabolism 2016 24 4 542 554 10.1016/j.cmet.2016.08.010 27641099 PMC5061633 Yarla et al. (2016)

Yarla NS Bishayee A Sethi G Reddanna P Kalle AM Dhananjaya BL

Dowluru KS Chintala R Duddukuri GR Targeting arachidonic acid pathway by natural products for cancer prevention and therapy Seminars in Cancer Biology 2016 40–41 48 81 10.1016/j.semcancer.2016.02.001 26853158 Yoshida et al. (1999)

Yoshida T Sakane N Umekawa T Kogure A Kondo M Kumamoto K

Kawada T Nagase I Saito M Nicotine induces uncoupling protein 1 in white adipose tissue of obese mice International Journal of Obesity and Related Metabolic Disorders 1999 23 6 570 575 10.1038/sj.ijo.0800870 10411229 Yu et al. (2017)

Yu F Ao M Zheng X Li N Xia J Li Y Li D Hou Z Qi Z Chen XD

PEG-lipid-PLGA hybrid nanoparticles loaded with berberine-phospholipid complex to facilitate the oral delivery efficiency Drug Delivery 2017 24 1 825 833 10.1080/10717544.2017.1321062 28509588 PMC8241132 Zhang et al. (2014b)

Zhang Y Li R Meng Y Li S Donelan W Zhao Y Qi L Zhang M

Wang X Cui T Yang LJ Tang D Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling Diabetes 2014b 63 2 514 525 10.2337/db13-1106 24150604 PMC13117908 Zhang et al. (2008)

Zhang Y Li X Zou D Liu W Yang J Zhu N Huo L Wang M

Hong J Wu P Ren G Ning G Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine The Journal of Clinical Endocrinology & Metabolism 2008 93 7 2559 2565 10.1210/jc.2007-2404 18397984 Zhang et al. (2015)

Zhang J Tang H Deng R Wang N Zhang Y Wang Y Liu Y Li F

Wang X Zhou L Berberine suppresses adipocyte differentiation via decreasing CREB transcriptional activity PLOS ONE 2015 10 4 e0125667 10.1371/journal.pone.0125667 25928058 PMC4415922 Zhang et al. (2010)

Zhang H Wei J Xue R Wu JD Zhao W Wang ZZ Wang SK Zhou ZX

Song DQ Wang YM Pan HN Kong WJ Jiang JD Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression Metabolism 2010 59 2 285 292 10.1016/j.metabol.2009.07.029 19800084 Zhang et al. (2020)

Zhang L Wu X Yang R Chen F Liao Y Zhu Z Wu Z Sun X

Wang L Effects of berberine on the gastrointestinal microbiota Frontiers in Cellular and Infection Microbiology 2020 10 588517 10.3389/fcimb.2020.588517 33680978 PMC7933196 Zhang et al. (2014a)

Zhang Q Xiao X Li M Li W Yu M Zhang H Ping F Wang Z

Zheng J Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine BMC Complementary and Alternative Medicine 2014a 14 1 188 10.1186/1472-6882-14-188 24912407 PMC4057525 Zhang et al. (2014c)

Zhang Z Zhang H Li B Meng X Wang J Zhang Y Yao S Ma Q

Jin L Yang J Wang W Ning G Berberine activates thermogenesis in white and brown adipose tissue Nature Communications 2014c 5 5493 10.1038/ncomms6493 25423280 Ziqubu et al. (2023)

Ziqubu K Dludla PV Mthembu SXH Nkambule BB Mabhida SE

Jack BU Nyambuya TM Mazibuko-Mbeje SE An insight into brown/beige adipose tissue whitening, a metabolic complication of obesity with the multifactorial origin Frontiers in Endocrinology 2023 14 1114767 10.3389/fendo.2023.1114767 36875450 PMC9978510